Barinthus Biotherapeutics plc, headquartered in Germantown, Md., released its financial report for the quarter ending March 31, 2026. Operating under the ticker symbol BRNS on NASDAQ, the company, specializing in immunology and inflammation, emphasized their aim to create treatments fostering immune tolerance and potentially curative impacts. The announcement included an update on the corporate progress of Barinthus Bio.